NASDAQ:AUPH
Aurinia Pharmaceuticals Inc Stock News
$5.10
-0.0700 (-1.35%)
At Close: May 03, 2024
3 Healthcare Companies With Revenue Spiking 100% or More
08:00pm, Monday, 02'nd May 2022 The Motley Fool
Here's why three Fool.com contributors are bullish on Outset Medical, Aurinia Pharmaceuticals, and Shockwave Medical.
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analyst Ratings for Aurinia Pharmaceuticals
03:08pm, Thursday, 28'th Apr 2022 Benzinga
Analysts have provided the following ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
NEW YORK, March 12, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) resulting from allegations that Aurinia may have issued materially misleading business information to the investing public.
AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation AUPH
10:53pm, Friday, 11'th Mar 2022 NewMediaWire
AUPH INVESTOR NOTICE:
Aurinia gains the most in three months on above average volume
07:19pm, Wednesday, 09'th Mar 2022 Seeking Alpha
The shares of the commercial-stage biopharmaceutical company Aurinia Pharmaceuticals <> have added more than a tenth on Wednesday to record the biggest intraday gain in over…
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
02:10pm, Tuesday, 08'th Mar 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ:AUPH) stock. These analysts are typically employed by large Wall Street banks and tasked with underst
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
02:10pm, Tuesday, 08'th Mar 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ: AUPH ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 These 4 analysts have an average price target of $27.75 versus the current price of Aurinia Pharmaceuticals at $10.67, implying upside. Below is a summary of how these 4 analysts rated Aurinia … Full story available on Benzinga.com
10 Biggest Price Target Changes For Tuesday
12:04pm, Tuesday, 08'th Mar 2022 Benzinga
Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday.
Telsey Advisory Group cut Capri Holdings Limited (NYSE:
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation – AUPH
05:15pm, Monday, 07'th Mar 2022 Business Wire
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) resulting from allegations that Aurinia may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Aurinia securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr
Aurinia Pharmaceuticals gains on report investors pushing for sale
03:50pm, Monday, 07'th Mar 2022 Seeking Alpha
Aurinia Pharmaceuticals (AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic review.Aurinia holders, led…
Despite Market Reaction, Aurinia Pharmaceuticals Is On Track And Ahead Of Schedule
05:13am, Monday, 07'th Mar 2022
Aurinia Pharmaceuticals, along with biotechs in general, has been beaten down recently.
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
09:31pm, Thursday, 03'rd Mar 2022 Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presenta
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
04:31pm, Thursday, 03'rd Mar 2022
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presentat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurinia Pharmaceuticals Inc. - AUPH
03:00am, Thursday, 03'rd Mar 2022 PR Newswire
NEW YORK, March 2, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ: AUPH). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980….